Equities

Aarti Pharmalabs Ltd

AARTIPHARM:NSI

Aarti Pharmalabs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)654.70
  • Today's Change1.55 / 0.24%
  • Shares traded164.67k
  • 1 Year change+63.68%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 10:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,0079901,603
Total Receivables, Net5,8934,5243,882
Total Inventory6,4946,0204,755
Prepaid expenses612342
Other current assets, total0.00----
Total current assets13,45611,55810,281
Property, plant & equipment, net10,9329,8619,453
Goodwill, net181818
Intangibles, net753398224
Long term investments368355322
Note receivable - long term1812515
Other long term assets1139486
Total assets25,82122,30920,399
LIABILITIES
Accounts payable3,7833,4682,146
Accrued expenses153130--
Notes payable/short-term debt2,6412,1383,377
Current portion long-term debt/capital leases458.1616
Other current liabilities, total323172268
Total current liabilities6,9445,9165,807
Total long term debt1677.1521
Total debt2,8532,1533,414
Deferred income tax1,079788707
Minority interest------
Other liabilities, total61130.03
Total liabilities8,2516,7246,534
SHAREHOLDERS EQUITY
Common stock4534532.50
Additional paid-in capital4,4034,4034,403
Retained earnings (accumulated deficit)12,63310,6438,900
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total8185559
Total equity17,57015,58513,865
Total liabilities & shareholders' equity25,82122,30920,399
Total common shares outstanding919191
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.